Cargando…
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
SIMPLE SUMMARY: HER2+ and triple negative breast cancers are widely known for their aggressiveness, frequent resistance to treatment and poor prognosis. Neoadjuvant management has provided promising results for both subtypes, but there is still a subset of patients with no or low response. Consequen...
Autores principales: | Pons, Laura, Hernández, Laura, Urbizu, Aintzane, Osorio, Paula, Rodríguez-Martínez, Paula, Castella, Eva, Muñoz, Ana, Sanz, Carolina, Arnaldo, Laura, Felip, Eudald, Quiroga, Vanesa, Tapia, Gustavo, Margelí, Mireia, Fernandez, Pedro Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296027/ https://www.ncbi.nlm.nih.gov/pubmed/37370679 http://dx.doi.org/10.3390/cancers15123068 |
Ejemplares similares
-
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022) -
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022) -
Obtaining miRNA from Saliva—Comparison of Sampling and Purification Methods
por: Urbizu, Aintzane, et al.
Publicado: (2023) -
Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022) -
Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
por: Hardy-Werbin, Max, et al.
Publicado: (2019)